6月8日，德康医疗盘中上涨5.27%，报76.83美元/股，成交额7314.0万美元。
消息面上，德康医疗公布Connect研究最新数据，该里程碑式临床研究证实，G7持续血糖监测系统与GLP-1受体激动剂联合使用，可实现糖化血红蛋白平均降低1.4%，远超对照组0.2%的改善幅度。此外，G7与二甲双胍、SGLT2抑制剂等多种药物联用均展现出显著临床获益，为非胰岛素治疗的2型糖尿病患者提供了迄今最有力的CGM循证依据。该研究六个月延长期目前正在推进中。
德康医疗是连续血糖监测系统领域的领先企业，据公司估计，美国仍有超过900万名符合CGM报销条件的患者尚未使用相关设备，市场空间广阔。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.